WuXi Biologics 2269.HK
Behind drug makers' biologic medicines
9.80 % of fund value
Chinese company that develops and makes biologic drugs such as antibodies for drug companies worldwide
DAOL CHINA BIOTECH FUND
Shows where this fund stands in its group. Not investment advice · Data as of 4 Nov 2026
DAOL-CHINABIO invests through the master fund Hang Seng Biotech Index ETF (3069) 86.51%
This fundDAOL-CHINABIOThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Launched less than a year ago, so no 1-year rank yet
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 4 Nov 2026
Past performance is not a guarantee of future results
| 1W | 2W | 1M | 3M | 6M | MAX |
|---|---|---|---|---|---|
| +6.68% | +6.71% | −7.16% | +4.51% | +1.36% | −7.53% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −2.7 | −3.0 | −2.9 | −0.2 | −7.9 | −5.4 | +8.2 | +10.1 | +7.0 | −15.6 | +7.6 |
Largest drawdown in the selected period −27.03% Previous peak 23 Feb 2026 (NAV 10.1336) → Trough 17 Jun 2026 (NAV 7.3946) · Back to the previous peak on 30 Sep 2026, after 3 months
Currently −9.43% from the peak NAV of 10.1985 (6 Oct 2026)
Over 1 year, 40 funds have data · DAOL-CHINABIO has no data for this period yet
กองทุนเปิด ดาโอ ไชน่า ไบโอเทค จะเน้นลงทุนในหน่วยลงทุนของ Hang Seng Biotech Index ETF (กองทุนหลัก) Class A ในสกุลเงินฮ่องกงดอลลาร์ (HKD) เพียงกองทุนเดียว โดยเฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุน ทั้งนี้ กองทุนหลักเป็นกองทุนอีทีเอฟ ซึ่งจดทะเบียนซื้อขายในตลาดหลักทรัพย… Its largest holdings are CHINAAMC HS BIOTECH HKD INC 86.51% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 29 Jan 2026, its NAV has fallen as much as −27.03% from its peak.
Actual total expense ratio (TER) 1.96% a year, against a ceiling of 4.80%. Management fee 1.61%. Front-end fee 1.61%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 1 THB, subsequent purchases 1 THB. Buy orders accepted until 13:30, sell orders until 13:30, and redemption proceeds are paid T+3
Hedged at the manager's discretion. As of 30 Sep 2026, 73.46% of the value of its foreign investments was hedged
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Wuxi AppTec 603259.SS3.20%Chinese company that develops and makes biologic drugs such as antibodies for drug companies worldwide
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Chinese biotech developing cancer drug Tyvyt and the diabetes and weight loss drug mazdutide
Hospitals, medicines and medical equipment
Taobao, Tmall and Lazada online stores
Hospitals, medicines and medical equipment
Wuxi AppTec 603259.SSChinese company that researches, tests and makes drugs under contract for drug and biotech companies worldwide
Hospitals, medicines and medical equipment
Chinese biotech that brings cancer and immune disease drugs such as Vyvgart and Zejula to China
Based on the master fund's share of this fund's value (86.51% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 27 Oct 2026 · Illustrations are for explanation only, not individual stock recommendations
| · |
| −7.5* |